Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Medicines licensing

Olaratumab fast-tracked for approval across EU

A new cancer drug to treat certain adult patients with rare soft tissue sarcoma is being fast-tracked for conditional approval across the EU.

The European Medicines Agency (EMA) is proposing that olaratumab (Lartruvo; Eli Lilly) should be used in combination with doxorubicin in patients with advanced disease for whom surgery or radiotherapy is not suitable and who have not been previously treated with doxorubicin.

Soft tissue sarcoma occurs in tissues that support, surround or protect organs and accounts for around 2% of all cancer-related deaths. According to the EMA, between 40% and 60% of patients with this cancer will be in an advanced stage of the disease; only half live longer than five years and this prognosis has not improved over the past 40 years.

Olaratumab is a monoclonal antibody that targets platelet-derived growth factor receptor alpha (PDGFRα), which is present in high levels or is overactive in soft tissue sarcoma, causing cells to become cancerous. By attaching to PDGFRα on sarcoma cells, olaratumab blocks its activity, thereby slowing down the growth of the cancer.

The EMA’s proposal follows a recommendation from the Committee for Medicinal Products for Human Use based on the results of a phase II study that found patients given a combination of doxorubicin and olaratumab had a longer average survival of 11.8 months compared with patients taking doxorubicin alone.

The marketing authorisation is on condition that Eli Lilly provides results from an ongoing phase III study to confirm the earlier results.

The EMA’s recommendation will go to the European Commission for approval. If given the go-ahead, it is left to each individual member state to decide whether to make the product available in its national health system and to agree its price and reimbursement.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201745

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • European Medicines Agency building

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.